AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Preventing Infectious Complications of Glucocorticoids

Description

The discussion focuses on the infectious complications associated with glucocorticoid (steroid) therapy and strategies to prevent them. Key topics include identifying risk factors for infections, particularly Pneumocystis pneumonia (PCP), and when to consider prophylactic measures based on dosage and patient conditions. For instance, a threshold of 20 mg of prednisone daily for four weeks is noted as a risk factor for PCP, especially when combined with other immunosuppressive treatments. Case studies highlight patients who may require closer monitoring and prophylaxis, particularly those with additional risk factors like certain rheumatic diseases or chemotherapy. Vaccination considerations are also emphasized, such as avoiding live vaccines during high doses of steroids, while inactivated vaccines can be administered safely. Recommendations include screening for tuberculosis, hepatitis, and HIV in patients on long-term corticosteroids, as well as ensuring they are up to date with vaccinations before starting treatment. The overall take-home message stresses the importance of identifying at-risk patients and implementing strategies for infection prevention effectively.

View more

Conclusions

  • Glucocorticoids increase the risk of infections from various pathogens due to their immunosuppressive effects.
  • Patients receiving more than 20 mg of prednisone daily for four weeks or longer should be monitored for Pneumocystis pneumonia (PCP).
  • Chronic steroid use alone does not significantly raise the risk of PCP; additional risk factors must be present for prophylaxis to be warranted.
  • Common risk factors for PCP include transplant history, hematologic malignancies, and intensive immunosuppression combined with steroids.
  • Dermatology patients generally present lower PCP risk compared to others unless they have significant comorbid conditions.
  • Recommended prophylactic treatment for those at risk includes Trimethoprim-sulfamethoxazole (TMP-SMX).
  • Screening for tuberculosis, hepatitis B, hepatitis C, and HIV should be conducted before initiating high-dose steroid therapy.
  • Vaccinations should be updated prior to starting steroid therapy, particularly live vaccines, ideally two to four weeks before.
  • Live vaccines should be avoided in patients on high-dose steroids to prevent vaccine-related infections.
  • Prophylactic strategies and vaccinations must be tailored to individual patient risk assessments.
  • JAMA. 2023 Jul 11;330(2):182-183.
  • Mayo Clin Proc. 2007;82:1052-9.
  • J Am Acad Dermatol. 2010;63:815-23.
  • J Am Acad Dermatol. 2010;62:957-61.
  • JAMA. 2023 Nov 21;330(19):1908-1909.
  • Arthritis Rheum. 2006;55:19-26.
  • ACR Open Rheumatol. 2020;2(6):357.
  • J Am Acad Dermatol. 2017 Feb;76(2):191-198.